S&P 500   5,018.03 (+0.14%)
DOW   37,952.09 (+0.47%)
QQQ   421.92 (-0.35%)
AAPL   165.93 (-0.66%)
MSFT   403.98 (-0.07%)
META   497.10 (-0.94%)
GOOGL   155.28 (-0.47%)
AMZN   177.49 (-0.97%)
TSLA   150.32 (+0.26%)
NVDA   841.05 (-0.67%)
AMD   150.98 (-2.64%)
NIO   3.92 (-2.00%)
BABA   68.90 (+0.03%)
T   16.36 (+0.18%)
F   12.12 (+0.50%)
MU   110.35 (-1.41%)
GE   153.02 (+0.05%)
CGC   8.11 (+3.58%)
DIS   112.06 (-0.33%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.35 (+0.40%)
XOM   119.54 (+0.86%)
S&P 500   5,018.03 (+0.14%)
DOW   37,952.09 (+0.47%)
QQQ   421.92 (-0.35%)
AAPL   165.93 (-0.66%)
MSFT   403.98 (-0.07%)
META   497.10 (-0.94%)
GOOGL   155.28 (-0.47%)
AMZN   177.49 (-0.97%)
TSLA   150.32 (+0.26%)
NVDA   841.05 (-0.67%)
AMD   150.98 (-2.64%)
NIO   3.92 (-2.00%)
BABA   68.90 (+0.03%)
T   16.36 (+0.18%)
F   12.12 (+0.50%)
MU   110.35 (-1.41%)
GE   153.02 (+0.05%)
CGC   8.11 (+3.58%)
DIS   112.06 (-0.33%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.35 (+0.40%)
XOM   119.54 (+0.86%)
S&P 500   5,018.03 (+0.14%)
DOW   37,952.09 (+0.47%)
QQQ   421.92 (-0.35%)
AAPL   165.93 (-0.66%)
MSFT   403.98 (-0.07%)
META   497.10 (-0.94%)
GOOGL   155.28 (-0.47%)
AMZN   177.49 (-0.97%)
TSLA   150.32 (+0.26%)
NVDA   841.05 (-0.67%)
AMD   150.98 (-2.64%)
NIO   3.92 (-2.00%)
BABA   68.90 (+0.03%)
T   16.36 (+0.18%)
F   12.12 (+0.50%)
MU   110.35 (-1.41%)
GE   153.02 (+0.05%)
CGC   8.11 (+3.58%)
DIS   112.06 (-0.33%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.35 (+0.40%)
XOM   119.54 (+0.86%)
S&P 500   5,018.03 (+0.14%)
DOW   37,952.09 (+0.47%)
QQQ   421.92 (-0.35%)
AAPL   165.93 (-0.66%)
MSFT   403.98 (-0.07%)
META   497.10 (-0.94%)
GOOGL   155.28 (-0.47%)
AMZN   177.49 (-0.97%)
TSLA   150.32 (+0.26%)
NVDA   841.05 (-0.67%)
AMD   150.98 (-2.64%)
NIO   3.92 (-2.00%)
BABA   68.90 (+0.03%)
T   16.36 (+0.18%)
F   12.12 (+0.50%)
MU   110.35 (-1.41%)
GE   153.02 (+0.05%)
CGC   8.11 (+3.58%)
DIS   112.06 (-0.33%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.35 (+0.40%)
XOM   119.54 (+0.86%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$145.43
-0.2%
$156.32
$143.13
$175.97
$350.45B0.537.17 million shs852,989 shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.43
+0.2%
$27.14
$25.23
$40.37
$144.00B0.6141.95 million shs2.37 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.67%-2.04%-6.70%-9.84%-10.33%
Pfizer Inc. stock logo
PFE
Pfizer
-0.08%-3.61%-8.06%-10.27%-36.92%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.8752 of 5 stars
3.23.04.23.93.02.51.9
Pfizer Inc. stock logo
PFE
Pfizer
4.9902 of 5 stars
3.25.04.24.82.51.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$175.8620.92% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.35
Hold$36.8845.01% Upside

Current Analyst Ratings

Latest JNJ and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$169.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$181.00 ➝ $175.00
4/15/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/22/2024
Pfizer Inc. stock logo
PFE
Pfizer
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/13/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
3/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
2/28/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$181.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.12$13.73 per share10.59$28.57 per share5.09
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.46$2.98 per share8.54$15.81 per share1.61

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.049.0713.292.3945.26%36.43%15.01%7/18/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3670.649.181.153.62%10.88%4.91%5/1/2024 (Confirmed)

Latest JNJ and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/16/2024Q1 24
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.64$2.71+$0.07$3.22$21.39 billion$21.38 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    
1/23/202412/31/2023
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.28$2.29+$0.01$2.91$21.02 billion$21.40 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.763.27%+5.70%29.68%62 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.61%+2.57%466.67%15 Years

Latest JNJ and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.36%5/20/20245/21/20246/4/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.38
1.16
0.91
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.41 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

JNJ and PFE Headlines

SourceHeadline
Pfizer (NYSE:PFE) Hits New 1-Year Low at $25.26Pfizer (NYSE:PFE) Hits New 1-Year Low at $25.26
marketbeat.com - April 18 at 4:55 PM
Xponance Inc. Grows Position in Pfizer Inc. (NYSE:PFE)Xponance Inc. Grows Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 18 at 4:41 PM
Is Pfizer Stock A Sell As Shares Hit A 9-Year Low Amid The Search For Its Next Big Break?Is Pfizer Stock A Sell As Shares Hit A 9-Year Low Amid The Search For Its Next Big Break?
investors.com - April 18 at 1:01 PM
If Youd Invested $1,000 in Pfizer 5 Years Ago, Heres How Much Youd Have TodayIf You'd Invested $1,000 in Pfizer 5 Years Ago, Here's How Much You'd Have Today
fool.com - April 18 at 9:15 AM
Pfizer exec to join well-resourced venture capital firmPfizer exec to join well-resourced venture capital firm
thepharmaletter.com - April 18 at 9:10 AM
The 3 Most Overlooked Stocks Set for a Triple-Digit ComebackThe 3 Most Overlooked Stocks Set for a Triple-Digit Comeback
investorplace.com - April 17 at 5:48 PM
Pfizer-Connect Biopharma deal for anti-inflammatory agent endsPfizer-Connect Biopharma deal for anti-inflammatory agent ends
msn.com - April 17 at 2:42 PM
Pfizer Inc. (NYSE:PFE) Shares Acquired by KLCM Advisors Inc.Pfizer Inc. (NYSE:PFE) Shares Acquired by KLCM Advisors Inc.
marketbeat.com - April 17 at 1:39 PM
Pfizer (NYSE:PFE) Trading Down 0.8%Pfizer (NYSE:PFE) Trading Down 0.8%
marketbeat.com - April 17 at 12:42 PM
Connect Biopharma uncouples from Pfizer by scrapping long-standing eczema pactConnect Biopharma uncouples from Pfizer by scrapping long-standing eczema pact
fiercebiotech.com - April 17 at 9:42 AM
Pfizers academic-partnered R&D unit is scrapped as part of cost-cutting measuresPfizer's academic-partnered R&D unit is scrapped as part of cost-cutting measures
fiercebiotech.com - April 17 at 9:42 AM
HealthInvest Partners AB Acquires Shares of 42,820 Pfizer Inc. (NYSE:PFE)HealthInvest Partners AB Acquires Shares of 42,820 Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 16 at 6:50 PM
Pfizers Doldrums, Just A Bad Case Of COVID-19?Pfizer's Doldrums, Just A Bad Case Of COVID-19?
seekingalpha.com - April 16 at 2:34 PM
Pfizer (NYSE:PFE) Stock Price Down 0.2%Pfizer (NYSE:PFE) Stock Price Down 0.2%
marketbeat.com - April 16 at 2:02 PM
Pfizers (PFE) Overweight Rating Reaffirmed at Cantor FitzgeraldPfizer's (PFE) Overweight Rating Reaffirmed at Cantor Fitzgerald
americanbankingnews.com - April 16 at 4:26 AM
Why the Market Dipped But Pfizer (PFE) Gained TodayWhy the Market Dipped But Pfizer (PFE) Gained Today
zacks.com - April 15 at 6:51 PM
Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A TalkPfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk
seekingalpha.com - April 15 at 5:39 PM
Pfizer (NYSE:PFE) Trading Up 0.7%Pfizer (NYSE:PFE) Trading Up 0.7%
marketbeat.com - April 15 at 3:37 PM
A Closer Look at Pfizers Options Market DynamicsA Closer Look at Pfizer's Options Market Dynamics
benzinga.com - April 15 at 12:38 PM
Cullen Investment Group LTD. Takes Position in Pfizer Inc. (NYSE:PFE)Cullen Investment Group LTD. Takes Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 15 at 11:27 AM
Cantor Fitzgerald Reaffirms "Overweight" Rating for Pfizer (NYSE:PFE)Cantor Fitzgerald Reaffirms "Overweight" Rating for Pfizer (NYSE:PFE)
marketbeat.com - April 15 at 11:21 AM
Is Pfizer Stock a Buy?Is Pfizer Stock a Buy?
fool.com - April 15 at 8:45 AM
Pfizer’s Velsipity UK approval to raise competition in ulcerative colitis marketPfizer’s Velsipity UK approval to raise competition in ulcerative colitis market
biopharma-reporter.com - April 15 at 7:37 AM
Want $1,000 in Annual Dividend Income? Invest $13,200 in These Ultra-High-Yield Dividend Stocks.Want $1,000 in Annual Dividend Income? Invest $13,200 in These Ultra-High-Yield Dividend Stocks.
fool.com - April 15 at 4:53 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.